StockMarketWire.com - Indivior said it had presented data from two studies evaluating efficacy and long-term safety of a once-monthly injection of a treatment of moderate-to-severe opioid use disorder.

The so-called Recover study found that 75% of patients treated with the Sublocade treatment who had received 12 once-monthly doses in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended.

An 18-month safety study reported no new safety issues.

The results were reported at the 50th Annual Conference of the American Society of Addiction Medicine in Orlando, Florida.

'Reocver is assessing real-world outcomes in patients,' chief scientific officer Christian Heidbreder said.

'We have invested in this research to help answer questions about how medication-assisted treatment can help patients with opioid use disorder maintain recovery in their communities and live healthier lives.'






At 1:45pm: [LON:INDV] Indivior Plc share price was -0.39p at 97.51p



Story provided by StockMarketWire.com